Cardiovascular disease in haemodialysis and peritoneal dialysis: Arguments pro haemodialysis

Nephrology Dialysis Transplantation

Volumn 22, Issue 1, 2007, Pages 59-63

  Segall, Liviu ^a   Covic, Adrian ^a  

^a C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

Author keywords

Congestive heart failure; Haemodialysis; Peritoneal dialysis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ARGININE DERIVATIVE; DIALYSIS FLUID; DIMETHYLARGININE; ERYTHROPOIETIN; HOMOCYSTEINE; ICODEXTRIN; IRON; PHOSPHATE; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DYSLIPIDEMIA; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY FAILURE; MORTALITY; OUTCOMES RESEARCH; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SODIUM RESTRICTION; SURVIVAL RATE; UREMIA;

CARDIOVASCULAR DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; PREVALENCE; RENAL DIALYSIS; RISK; RISK FACTORS; TREATMENT OUTCOME; UREMIA;

EID: 33845979496     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl643     Document Type: Article

References (49)

1. Goodkin DA, Young EW, Kurokawa K, Prutz KG, Levin NW. Mortality among hemodialysis patients in Europe, Japan, and the United States: Case-mix effects. Am J Kidney Dis 2004; 44 [Suppl 2]: 16-21
2. Trespalacios FC, Taylor AJ, Agodoa LY, Bakris GL, Abbott KC. Heart failure as a cause for hospitalisation in chronic dialysis patients. Am J Kidney Dis 2003; 41: 1267-1277
3. Stack AG, Molony DA, Rahman NS, Dosekun A, Murthy B. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney Int 2003; 64: 1071-1079
4. Ganesh SK, Hulbert-Shearon T, Port FK, Eagle K, Stack AG. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol 2003; 14: 415-424
5. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int 2004; 66: 2389-2401
6. Jaar BG, Coresh J, Plantinga LC et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005; 143: 174-183
7. Lee HB, Song KI, Kim JH, Cha MK, Park MS. Dialysis in patients with diabetic nephropathy: CAPD versus hemodialysis. Perit Dial Int 1996; 16 [Suppl 1]: S269-S274
8. Collins AJ, Hao W, Xia H et al. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 1999; 34: 1065-1074
9. Collins AJ, Weinhandl E, Snyder JJ, Chen SC, Gilbertson D. Comparison and survival of hemodialysis and peritoneal dialysis in the elderly. Semin Dial 2002; 15: 98-102
10. Hamburger RJ, Christ PG, Morris PA, Luft FC. Hypertension in dialysis patients: Does CAPD provide an advantage? Adv Perit Dial 1989; 5: 91-96
11. Lameire N. Cardiovascular risk factors and blood pressure control in continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13 [Suppl 2]: S394-S395
12. Dasgupta I, Burden R. Blood pressure control before and after starting dialysis. Nephron Clin Pract 2005; 99: C86-c91
13. Bianchi G. Hypertension in chronic renal failure and end-stage renal disease patients treated with haemodialysis or peritoneal dialysis. Nephrol Dial Transplant 2000; 15 [Suppl 5]: 105-110
14. Menon M, Naimark D, Bargman J, Vas S, Oreopoulos D. Longterm blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 2001; 16: 2207-2213
15. Ates K, Nergizoglu G, Keven K et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001; 60: 767-776
16. Enia G, Mallamaci F, Benedetto FA et al. Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrol Dial Transplant 2001; 16: 1459-1464
17. Konings CJ, Kooman JP, Schonck M et al. Fluid status in CAPD patients is related to peritoneal transport and residual renal function: Evidence from a longitudinal study. Nephrol Dial Transplant 2003; 18: 797-803
18. Margetts PJ, Churchill DN. Acquired UF dysfunction in peritoneal dialysis patients. J Am Soc Nephrol 2002; 13: 2787-2794
19. Woodrow G, Oldroyd B, Stables G, Gibson J, Turney JH, Brownjohn AM. Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis. Nephrol Dial Transplant 2000; 15: 862-866
20. Johnson DW, Arndt M, O'Shea A, Watt R, Hamilton J, Vincent K. Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload. BMC Nephrol 2001; 2: 2
21. Davies SJ, Woodrow G, Donovan K et al. Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-2344
22. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int 2000; 20: 516-523
23. MacRae JM, Pandeya S, Humen DP, Krivitski N, Lindsay RM. Arteriovenous fistula-associated high-output cardiac failure: A review of mechanisms. Am J Kidney Dis 2004; 43: E17-E21
24. Abbott KC, Trespalacios FC, Agodoa LY. Arteriovenous fistula use and heart disease in long-term elderly hemodialysis patients: Analysis of United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. J Nephrol 2003; 16: 822-830
25. Foley RN, Parfrey PS, Harnett JD et al. The impact of anemia on cardiomyopathy morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53-61
26. Snyder JJ, Foley RN, Gilbertson DT, Vonesh EF, Collins AJ. Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States. J Am Soc Nephrol 2004; 15: 174-179
27. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 2001; 104: 2996-3007
28. Liu J, Rosner MH. Lipid abnormalities associated with end-stage renal disease. Semin Dial 2006; 19: 32-40
29. Cheung AK, Sarnak MJ, Yan G et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353-362
30. Vanholder R, Argiles A, Baurmeister U et al. Uremic toxicity: Present state of the art. Int J Artif Organs 2001; 24: 695-725
31. Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ. Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 2005; 16: 1471-1485
32. Zoccali C, Enia G, Tripepi G, Panuccio V, Mallamaci F. Clinical epidemiology of major nontraditional risk factors in peritoneal dialysis patients. Perit Dial Int 2005; 25 [Suppl 3]: S84-S87
33. Covic A, Goldsmith DJ, Florea L, Gusbeth-Tatomir P, Covic M. The influence of dialytic modality on arterial stiffness, pulse wave reflections and vasomotor function. Perit Dial Int 2004; 24: 365-372
34. Konings CJ, Dammers R, Rensma PL et al. Arterial wall properties in patients with renal failure. Am J Kidney Dis 2002; 39: 1206-1212
35. Mimura T, Takenaka T, Kanno Y, Aoki H, Ohshima J, Suzuki H. Comparison of changes in pulse wave velocity in patients on continuous ambulatory peritoneal dialysis and hemodialysis one year after introduction of dialysis therapy. Adv Perit Dial 2005; 21: 139-145
36. Sigrist M, Bungay P, Taal MW, McIntyre CW. Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant 2006; 21: 707-714
37. Gunal AI, Ilkay E, Kirciman E, Karaca I, Dogukan A, Celiker H. Blood pressure control and left ventricular hypertrophy in long-term CAPD and hemodialysis patients: A crosssectional study. Perit Dial Int 2003; 23: 563-567
38. Canziani ME, Cendoroglo Neto M, Saragoca MA et al. Hemodialysis versus continuous ambulatory peritoneal dialysis: Effects on the heart. Artif Organs 1995; 19: 241-244
39. Konings CJ, Kooman JP, Schonck M et al. Fluid status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis. Perit Dial Int 2002; 22: 477-487
40. Koc M, Toprak A, Tezcan H, Bihorac A, Akoglu E, Ozener IC. Uncontrolled hypertension due to volume overload contributes to higher left ventricular mass index in CAPD patiens. Nephrol Dial Transplant 2002; 17: 1661-1666
41. Huting J, Alpert MA. Progression of left ventricular hypertrophy in end-stage renal disease treated by continuous ambulatory peritoneal dialysis depends on hypertension and hypercirculation. Clin Cardiol 1992; 15: 190-196
42. Wang AY, Wang M, Woo J et al. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002; 62: 639-647
43. Takeda K, Nakamoto M, Baba M et al. Echocardiographic evaluation in long-term continuous ambulatory peritoneal dialysis compared with the hemodialysis patients. Clin Nephrol 1998; 49: 308-312
44. Enia G, Mallamaci F, Benedetto FA et al. Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrol Dial Transplant 2001; 16: 1459-1464
45. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998; 54: 1720-1725
46. Asci G, Ozkahya M, Duman S, Toz H, Erten S, Ok E. Volume control is associated with better cardiac function in long-term peritoneal dialysis patients. Perit Dial Int 2006; 26: 85-88
47. Konings CJ, Kooman JP, Schonck M et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: A randomized study. Kidney Int 2003; 63: 1556-1563
48. Locatelli F, Marcelli D, Conte F et al. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol 2001; 12: 2411-2417
49. Cice G, Ferrara L, D'Andrea A et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438-1444